nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2022, 04, v.41;No.414 396-400
益气健脾方治疗2型糖尿病合并肥胖临床观察
基金项目(Foundation): 山东省中医药科技发展计划项目(编号:2017-370)
邮箱(Email):
DOI: 10.16295/j.cnki.0257-358x.2022.04.008
摘要:

目的:探讨益气健脾方治疗2型糖尿病合并肥胖患者的临床疗效。方法:选取2型糖尿病合并肥胖患者85例,按照随机数字表法分为对照组41例与观察组44例。对照组给予饮食控制及运动治疗,并口服二甲双胍等降糖药物控制血糖;观察组在对照组基础上联合益气健脾方治疗。治疗3个月后比较两组患者治疗前后血糖指标、体质量指标、中医症状评分、临床疗效及不良反应发生情况。结果:治疗后,两组患者的空腹血糖、餐后2 h血糖、体质量及体质量指数(BMI)、中医症状评分均低于治疗前,差异有统计学意义(P<0.05或P<0.01);且观察组低于对照组,差异有统计学意义(P<0.05或P<0.01)。两组治疗后糖化血红蛋白(HbA1c)均较治疗前降低(P<0.01),但组间比较差异无统计学意义(P>0.05)。观察组临床疗效优于对照组,差异有统计学意义(P<0.05);观察组患者未发生不良反应事件,对照组发生低血糖1例,未出现其他不良反应,差异无统计学意义(P>0.05)。结论:益气健脾方治疗2型糖尿病合并肥胖安全有效,能够明显降低患者体质量,减轻患者临床症状,且未增加不良反应的发生。

Abstract:

Objective:To investigate the clinical effect of Yiqi Jianpi Formula(益气健脾方) on patients with type 2 diabetes mellitus combined with obesity. Methods:Total 85 patients with type 2 diabetes combined with obesity were selected. The patients were randomly divided into the control group(41 cases) and the observation group( 44 cases). The control group was given diet control and exercise therapy, and oral metformin and other hypoglycemic drugs to control blood glucose. On the basis of the treatment of the control group,the observation group was treated with Yiqi Jianpi Formula. After 3 months of treatment,the blood glucose index,body weight index,traditional Chinese medicine(TCM) symptom score,clinical efficacy and adverse reactions of the two groups were compared. Results:After treatment,the fasting blood glucose,2-hour postprandial blood glucose,body weight,body mass index(BMI) and TCM symptom scores of the two groups were lower than those before treatment,the differences were statistically significant(P<0.05 or P <0.01). The observation group was significantly lower than the control group,the differences were statistically significant(P <0.05 or P <0.01). The glycosylated hemoglobin(HbA1c) in two groups were lower than that before treatment(P<0.01). But the difference of the two groups was not statistically significant(P>0.05). The clinical effect of the observation group was better than that of the control group,the difference was statistically significant(P<0.05). There were no adverse events in the observation group,there was one case of hypoglycemia in the control group,and there was no other adverse reactions,the difference was not statistically significant(P>0.05). Conclusions:Yiqi Jianpi Formula is effective and safe in treating type 2 diabetes combined with obesity. It can significantly reduce the weight of patients,relieve the clinical symptoms of patients,and does not increase the incidence of adverse reactions.

参考文献

[1]张敏,李建香,马文静,等.我国糖尿病流行病学和疾病经济负担研究现状[J].世界最新医学信息文摘,2017,17(56):176.

[2]杨文英.中国糖尿病的流行特点及变化趋势[J].中国科学:生命科学,2018,48(8):812-819.

[3]方朝晖,仝小林,段俊国,等.糖尿病前期中医药循证临床实践指南[J].中医杂志,2017,58(3):268-272.

[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):53.

[5]周仲瑛.中医内科学[M].北京:中国中医药出版社,1997:34.

[6]中华医学会内分泌学分会.中国2型糖尿病合并肥胖综合管理专家共识[J].中华糖尿病杂志,2016,8(11):662-666.

[7]孙子林,刘莉莉.《中国糖尿病运动治疗指南》解读[J].国际内分泌代谢杂志,2013,33(6):4.

[8]郑筱萸.中医新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:232-237.

[9]侯宇方.健脾化湿方对脾虚湿困型2型糖尿病脂代谢异常的临床疗效[D].太原:山西中医药大学,2020.

[10]林俊良.参术荷叶汤治疗肥胖型2型糖尿病脾虚痰浊证的临床观察[D].南京:南京中医药大学,2020.

[11]《光明日报》.《中国居民营养与慢性病状况报告(2015年)》发布[J].上海医药,2015,36(13):79.

[12]徐曼曼,韦妮娜,崔翰明,等.从“虚气留滞”论初发型2型糖尿病的病因病机[J].中国医药导报,2020,17(19):116-119.

[13]杨媛.薄氏腹针治疗肥胖型2型糖尿病临床疗效观察研究[D].北京:北京中医药大学,2014.

[14]郝志婧.健脾化湿法干预糖尿病前期(脾虚痰湿证)的理论与临床研究[D].天津:天津中医药大学,2020.

[15]刘添娇.小陷胸汤合枳术汤加减治疗脾虚湿热型2型糖尿病的临床疗效观察[D].济南:山东中医药大学,2019.

[16]何茹.中医理论对肥胖病因病机的认识[C]//甘肃省中医药学会.甘肃省中医药学会2013年学术年会论文集.庆阳:甘肃省中医药学会,2013:2.

[17]徐小娟,刘丹,张炜宁,等.参苓白术散加减对2型糖尿病患者胰岛素敏感指数的影响[J].中医药临床杂志,2015,27(7):954-956.

[18]虎喜成,马玉宝,楚国庆,等.健脾化湿法治疗肥胖型2型糖尿病40例[J].中国中医药现代远程教育,2019,17(5):63-65.

[19]梅全喜.简明实用中药药理手册[M].北京:人民卫生出版社,2010.

[20]张晓娟,左冬冬.白术化学成分及药理作用研究新进展[J].中医药信息,2018,35(6):101-106.

基本信息:

DOI:10.16295/j.cnki.0257-358x.2022.04.008

中图分类号:R259

引用信息:

[1]杜积慧,于文娟,邴蕾蕾.益气健脾方治疗2型糖尿病合并肥胖临床观察[J],2022,41(04):396-400.DOI:10.16295/j.cnki.0257-358x.2022.04.008.

基金信息:

山东省中医药科技发展计划项目(编号:2017-370)

检 索 高级检索